Zaltoprofen - CAS 74711-43-6
Catalog number: 74711-43-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H14O3S
Molecular Weight:
298.36
COA:
Inquire
Targets:
Cox-2 | COX
Description:
An inhibitor of Cox-1 and Cox-2；A nonsteroidal anti-inflammatory drug
Publication citing BOC Sciences Products
1. Effect of imidacloprid ingestion on immune responses to porcine reproductive and respiratory syndrome virus
2. Specificity Screening of Potential Active Components from Moutan Cortex for Rat Mesangial Cells HBZY-1 by Cell Membrane Immobilized Chromatography
3. Unique anti‐myeloma activity by thiazolidine‐2, 4‐dione compounds with Pim inhibiting activity
4. Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution
5. Colloid, adhesive and release properties of nanoparticular ternary complexes between cationic and anionic polysaccharides and basic proteins like bone morphogenetic protein BMP-2
6. Beta Cyclodextrin Derivatives as Protein Aggregation Modulators

>> More

Brife Description:
An inhibitor of Cox-1 and Cox-2;A nonsteroidal anti-inflammatory drug
Appearance:
Off-White to pale yellow crystalline solid.
Synonyms:
10,11-dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid; Zaltoprofen; CN 100; CN-100; CN100; WY-21743; WY 21743; WY21743
Solubility:
DMSO 60 mg/mL (201.09 mM);Ethanol 31 mg/mL (103.9 mM)
Storage:
3 years -20°C powder;6 months-80°C in solvent
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
Melting Point:
129-131°C
InChIKey:
MUXFZBHBYYYLTH-UHFFFAOYSA-N
InChI:
1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
Canonical SMILES:
CC(C1=CC2=C(C=C1)SC3=CC=CC=C3C(=O)C2)C(=O)O
1.Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial.
Chen J1, Dong F1, Chen W2, Sun X3, Deng Y4, Hong J5, Zhang M6, Yang W1, Liu Z7, Xie L8. Chin Med J (Engl). 2014;127(13):2407-12.
BACKGROUND: Dry eye is a multifactorial disease of the tears and the ocular surface. This study aimed to investigate the clinical efficacy of a non-steroidal anti-inflammatory drug, pranoprofen, in the treatment of dry eye.
2.Oleic Acid Coated Gelatin Nanoparticles Impregnated Gel for Sustained Delivery of Zaltoprofen: Formulation and Textural Characterization.
Pawar S1, Pande V2. Adv Pharm Bull. 2015 Nov;5(4):537-48. doi: 10.15171/apb.2015.073. Epub 2015 Nov 30.
PURPOSE: In the present study, we have formulated zaltoprofen loaded, surface decorated, biodegradable gelatin nanogel and evaluated its texture characterization.
3.Effect of topical nonsteroidal anti-inflammatory drugs and nuclear hardness on maintenance of mydriasis during phacoemulsification surgery.
Liu C1, Liu Y, Ye S, Liu L, Zhang W, Wu M. J Ocul Pharmacol Ther. 2014 Dec;30(10):831-6. doi: 10.1089/jop.2013.0244.
PURPOSE: To compare the effects of topical nonsteroidal anti-inflammatory drugs on pupil dilation maintenance during phacoemulsification cataract surgery and quantify the relationships between pupil size change and nuclear hardness.
4.Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen.
Abrego G1, Alvarado HL, Egea MA, Gonzalez-Mira E, Calpena AC, Garcia ML. J Pharm Sci. 2014 Oct;103(10):3153-64. doi: 10.1002/jps.24101. Epub 2014 Aug 4.
Pranoprofen (PF)-loaded poly (lactic-co-glycolic) acid (PLGA) nanoparticles (NPs) were optimized and characterized as a means of exploring novel formulations to improve the biopharmaceutical profile of this drug. These systems were prepared using the solvent displacement technique, with polyvinyl alcohol (PVA) as a stabilizer. A factorial design was applied to study the influence of several factors (the pH of the aqueous phase and the stabilizer, polymer and drug concentrations) on the physicochemical properties of the NPs. After optimization, the study was performed at two different aqueous phase pH values (4.50 and 5.50), two concentrations of PF (1.00 and 1.50 mg/mL), three of PVA (5, 10, and 25 mg/mL), and two of PLGA (9.00 and 9.50 mg/mL). These conditions produced NPs of a size appropriate particle size for ocular administration (around 350 nm) and high entrapment efficiency (80%). To improve their stability, the optimized NPs were lyophilized.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products

CAS 13220-57-0 Tryptanthrin

Tryptanthrin
(CAS: 13220-57-0)

A potent inhibitor of Cox-2, IDO and NOS II

CAS 50-78-2 Aspirin

Aspirin
(CAS: 50-78-2)

A salicylate and irreversible COX1 and COX2 inhibitor

CAS 322-79-2 Triflusal

Triflusal
(CAS: 322-79-2)

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.

CAS 53716-49-7 Carprofen

Carprofen
(CAS: 53716-49-7)

A COX-2 inhibitor; A non-steroidal anti-inflammatory drug

CAS 80382-23-6 Loxoprofen Sodium

Loxoprofen Sodium
(CAS: 80382-23-6)

The parent acid, loxoprofen, is a prodrug that is rapidly converted to its active trans-alcohol metabolite following oral administration.

CAS 123663-49-0 Iguratimod

Iguratimod
(CAS: 123663-49-0)

Iguratimod(T-614) is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis fac...

FR-188582
(CAS: 189699-82-9)

FR-188582, with anti-inflammatory and ulcerogenic properties, is a highly selective inhibitor of COX-2 with IC50= 0.017 microM.

CAS 220991-20-8 Lumiracoxib

Lumiracoxib
(CAS: 220991-20-8)

A novel, selective COX-2 inhibitor; Phase 4

Chemical Structure

CAS 74711-43-6 Zaltoprofen

Quick Inquiry

Verification code

Featured Items